ORLANDO, Fla. — Gilead Sciences, facing declining sales from its existing blood cancer CAR-T therapies, has reported significant progress with anito-cel, its next-generation CAR-T therapy for multiple myeloma, at the annual meeting of the American Society of Hematology.
In the latest analysis of a pivotal-stage clinical trial, Gilead and its partner Arcellx revealed that among 117 patients enrolled, 96% exhibited a tumor response, with 74% achieving complete remission. This data suggests that anito-cel may offer a substantial benefit over existing treatments, particularly in a competitive market where efficacy and safety are paramount.
The implications of these findings are profound for stakeholders in the pharmaceutical industry, as they highlight the potential for anito-cel to not only revitalize Gilead’s portfolio but also reshape treatment paradigms for relapsed or refractory multiple myeloma. As the landscape evolves, the focus on durable responses and safety will likely influence regulatory and market dynamics for CAR-T therapies.
Use the database as your supply chain compass →
